Details of the Drug
General Information of Drug (ID: DM1VE6S)
| Drug Name | Acetyl-Ile-Glu-Thr-Asp-aldehyde | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
                        Ac-IETD-CHO; 191338-86-0; CHEMBL478695; Ac-Ile-Glu-Thr-Asp-CHO; SCHEMBL20257131; N-acetyl-Ile-Glu-Thr-Asp-aldehyde; ZINC14947181; BDBM50340547; Acetyl-isoleucyl-glutamyl-threonyl-aspartal; 338A860; N-Acetyl-Ile-Glu-Thr-Asp-al, ~99% (TLC), powder; (4S)-4-{[(1S,2R)-1-{[(2S)-1-carboxy-3-oxopropan-2-yl]carbamoyl}-2-hydroxypropyl]carbamoyl}-4-[(2S,3S)-2-acetamido-3-methylpentanamido]butanoic acid
                        
                     | ||||||||||||||||||||||
| Indication | 
 | ||||||||||||||||||||||
| Drug Type | Small molecular drug | ||||||||||||||||||||||
| Structure |  | ||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 3 | Molecular Weight (mw) | 502.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -2 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 16 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 7 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 10 | ||||||||||||||||||||||
| Chemical Identifiers | 
 | ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
|  Drug Therapeutic Target (DTT) | 
 | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
